| Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the … AJM Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... The Lancet Haematology 3 (5), e217-e227, 2016 | 528 | 2016 |
| Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS … AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, P La Rosée, ... The Lancet Haematology 4 (11), e510-e523, 2017 | 308 | 2017 |
| Drug-induced interstitial lung disease: a systematic review S Skeoch, N Weatherley, AJ Swift, A Oldroyd, C Johns, C Hayton, A Giollo, ... Journal of clinical medicine 7 (10), 356, 2018 | 284 | 2018 |
| Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, ... Annals of Oncology 28 (9), 2169-2178, 2017 | 253 | 2017 |
| Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... The Lancet 398 (10306), 1157-1169, 2021 | 210 | 2021 |
| Guidelines for the management of diffuse large B-cell lymphoma S Chaganti, T Illidge, S Barrington, P Mckay, K Linton, K Cwynarski, ... Br J Haematol 174 (1), 43-56, 2016 | 179 | 2016 |
| A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator's choice in patients with relapsed or refractory … MS Czuczman, M Trněný, A Davies, S Rule, KM Linton, ... Clinical cancer research 23 (15), 4127-4137, 2017 | 162 | 2017 |
| Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma CP Fox, EH Phillips, J Smith, K Linton, E Gallop-Evans, C Hemmaway, ... British journal of haematology 184 (3), 348-363, 2019 | 129 | 2019 |
| Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a … A Gibb, C Jones, A Bloor, S Kulkarni, T Illidge, K Linton, J Radford Haematologica 98 (4), 611, 2013 | 125 | 2013 |
| A clinician’s guide to biosimilars in oncology HS Rugo, KM Linton, P Cervi, JA Rosenberg, I Jacobs Cancer treatment reviews 46, 73-79, 2016 | 105 | 2016 |
| International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS … AJ Ferreri, K Cwynarski, E Pulczynski, M Ponzoni, M Deckert, LS Politi, ... Lancet Haematol 3 (5), e217-e227, 2016 | 99 | 2016 |
| Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours KM Linton, Y Hey, E Saunders, M Jeziorska, J Denton, CL Wilson, ... British journal of cancer 98 (8), 1403-1414, 2008 | 93 | 2008 |
| MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single … AJM Ferreri, JK Doorduijn, A Re, MG Cabras, J Smith, F Ilariucci, M Luppi, ... The Lancet Haematology 8 (2), e110-e121, 2021 | 70 | 2021 |
| Subcutaneous epcoritamab induces complete responses with an encouraging safety profile across relapsed/refractory B-cell non-Hodgkin lymphoma subtypes, including patients with … M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, ... Blood 136, 45-46, 2020 | 69 | 2020 |
| The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage SJ Howell, C Searle, V Goode, T Gardener, K Linton, RA Cowan, ... British journal of cancer 101 (4), 582-588, 2009 | 66 | 2009 |
| The MAGNOLIA trial: zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma S Opat, A Tedeschi, K Linton, P McKay, B Hu, H Chan, J Jin, ... Clinical Cancer Research 27 (23), 6323-6332, 2021 | 64 | 2021 |
| An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity L Cove-Smith, N Woodhouse, A Hargreaves, J Kirk, S Smith, SA Price, ... Toxicological Sciences 140 (1), 3-15, 2014 | 61 | 2014 |
| Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox, E Schorb, C Celico, ... Leukemia 36 (7), 1870-1878, 2022 | 60 | 2022 |
| Mantle cell lymphoma–advances in molecular biology, prognostication and treatment approaches E Silkenstedt, K Linton, M Dreyling British Journal of Haematology 195 (2), 162-173, 2021 | 56 | 2021 |
| Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma A Greystoke, JPB O'Connor, K Linton, MB Taylor, J Cummings, T Ward, ... British journal of cancer 104 (4), 719-725, 2011 | 56 | 2011 |
